Skip to content

Immunomodulatory mechanisms of Venom Immunotherapy

Immunomodulatory mechanisms of Venom Immunotherapy - WaspIT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31868
Enrollment
20
Registered
2008-11-19
Start date
2007-12-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insect venom allergy OR Yellow jacket allergy

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Severe systemic reaction after a wasp sting (Müller III - IV) -Positive Intracutaneous Skin Test for Wasp Venom (HEIC>= 0.5 at 1 ug) -Specific IgE wasp > 0.7 kU/l -Age between 18-65 years old -Patients shall give a written informed consent

Exclusion criteria

Exclusion criteria: -Atopy (defined as positive Phadiatop) -Severe asthma or emphysema, based on questionnaire; use of inhaled corticosteroids -Symptomatic coronary heart diseases or severe (even under treatment) arterial hypertension -Diseases with a contra-indication for the use of adrenaline -Severe Kidney disease -Treatment with β-blockers or immunosuppressive drugs -Immunotherapy with venom ever or during the last 5 years with inhalant allergens -Pregnancy, lactation or inadequate contraceptive measures -Alcohol or Drug abuse -Lack of co-operation or severe psychological disorders -Systemic mastocytosis

Design outcomes

Primary

MeasureTime frame
Detailed analysis and functional characterization of different regulatory T-cell subpopulations induced after VIT.

Secondary

MeasureTime frame
Determination of serum IgG, IgA and IgE - levels in correlation with IL-10 and TGFβ

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)